Stemson Therapeutics announced today that Kevin D’Amour has joined the company as Chief Scientific Officer. Kevin has 20 years of experience in cell therapy development, and spent ten years as Chief Scientific Officer at ViaCyte. While at Viacyte, Kevin took three stem cell-derived cell therapy products into the clinic to treat Type 1 Diabetes.
Stemson’s Vice President of R&D, Meghan Samberg, speaks about Stemson’s solution for hair follicle regeneration at the World Congress for Hair Research in Melbourne, Australia. See Link
Geoff Hamilton, CEO, recently spoke with The Science Advisory Board at the Alliance for Regenerative Medicine’s annual Meeting On The Mesa.
Stemson Therapeutics announced today that Paul Laikind, serial entrepreneur and former CEO of cell therapy company ViaCyte, has joined the Stemson Board of Directors. Paul brings significant company building and therapeutics development experience to the Stemson Board.
Stemson Therapeutics announced today the addition of Kapil Bharti, Ph.D. and George Murphy, M.D. to its Scientific Advisory Board. The addition of these distinguished leaders in the field significantly bolster Stemson’s efforts to restore human hair growth with a novel cell regeneration technology using the patient’s own cells to generate new hair follicles. Dr. Bharti is a Senior Investigator at the National Eye Institute at the National Institutes of Health and is a world renowned expert in regenerative medicine,
Stemson chosen as Select Technology Contributor at Global Hair Loss Summit; CEO Geoff Hamilton will give keynote address
Stemson Therapeutics has been chosen as Select Technology Contributor at the 2021 Global Hair Loss Summit (GHLS). GHLS is the premier virtual educational and networking event in the field of surgical hair restoration and all associated modalities. Founder and CEO Geoff Hamilton has been given the honor to present a keynote address entitled “Developing Induced Pluripotent Stem Cell Technology to Engineer a De Novo Supply of Hair Follicles to Treat Hair Loss.”’ Mr.
Stemson Therapeutics announced today the closing of a DCVC Bio-led $15 million Series A financing to advance development of Stemson’s proprietary therapeutic solution to cure hair loss. Genoa Ventures, AbbVie Ventures and other investors join in supporting Stemson’s efforts to restore human hair growth with a novel cell regeneration technology using the patient’s own cells to generate new hair follicles.
It’s estimated over 60 million people in the US are losing their hair. At least 20% of them are under the age of 30, and more than 30% of women will experience noticeable hair loss.
Its root causes are diverse, from autoimmune conditions, to long-lasting chemotherapy effects, to scarring and injuries, to genetics and age-related conditions.
Regardless of the cause, for most people, losing their hair hits them very hard emotionally.
Stemson target UK for expansion of research and development – with backing of impact investor Fortunis Capital
Biotech innovator Stemson are scoping out research and development investments in the UK to develop a revolutionary cure for baldness in partnership with London-based Fortunis Capital as their lead investor in the country, it was announced today.
San Diego-based Stemson Therapeutics is developing technology to restore human hair growth with a novel approach using the patient’s own cells to generate new hair follicles.
Funding from impact investor Fortunis will support research and development of the product solution and position the UK as a leading contender to conduct human clinical trials,
Stemson Therapeutics announced today a $7.5 million seed financing led by Allergan Aesthetics, an AbbVie Company, and impact investor Fortunis Capital to advance development of Stemson’s therapeutic solution to cure hair loss. Stemson aims to restore human hair growth with a novel approach using the patient’s own cells to generate new hair follicles.